Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

B

Behler CM, Vittinghoff E, Lin F, et al. "Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects." Clin. Infect. Dis.. 2007;44(10):1375-83.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Bhasin S, Parker RA, Sattler F, et al. "Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity." J. Clin. Endocrinol. Metab.. 2007;92(3):1049-57.
Blackard JT, Kang M, Sherman KE, Koziel MJames, Peters MG, Chung RT. "Effects of HCV treatment on cytokine expression during HCV/HIV coinfection." J. Interferon Cytokine Res.. 2006;26(11):834-8.
Blackard JT, Kang M, J St Clair B, et al. "Viral factors associated with cytokine expression during HCV/HIV co-infection." J. Interferon Cytokine Res.. 2007;27(4):263-9.
Blanchard-Horan C, Stocker V, Moran L, et al. "Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited Resource Trials." Appl Clin Trials. 2012;21(1):34-42.
Boltz VF, Bao Y, Lockman S, et al. "Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP." J. Infect. Dis.. 2014;209(5):703-10.
Boltz VF, Zheng Y, Lockman S, et al. "Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine." Proc. Natl. Acad. Sci. U.S.A.. 2011;108(22):9202-7.
Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. "Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment." J. Acquir. Immune Defic. Syndr.. 2006;43(4):433-5.
Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. "A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment." J. Interferon Cytokine Res.. 2011;31(6):481-3.
Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. "Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)." AIDS Res Ther. 2010;7:30.
Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. "Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2007;44(3):268-77.
Boswell KL, Paris R, Boritz E, et al. "Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection." PLoS Pathog.. 2014;10(1):e1003853.
Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use." Am. J. Clin. Nutr.. 2013;98(2):423-9.
Brehm JH, Lalama CM, Hughes MD, et al. "Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2011;56(4):344-8.
Brehm JH, Scott Y, Koontz DL, et al. "Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase." PLoS ONE. 2012;7(2):e31558.
Brenchley JM, Price DA, Schacker TW, et al. "Microbial translocation is a cause of systemic immune activation in chronic HIV infection." Nat. Med.. 2006;12(12):1365-71.
Bronke C, Almeida C-AM, McKinnon E, et al. "HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes." AIDS. 2013;27(6):899-905.
Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. "Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort." Antivir. Ther. (Lond.). 2009;14(6):853-8.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. "Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy." Diabetes Care. 2010;33(10):2244-9.
Brown TT, McComsey GA. "Osteopenia and osteoporosis in patients with HIV: a review of current concepts." Curr Infect Dis Rep. 2006;8(2):162-70.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Butler DM, Smith DM. "Serosorting can potentially increase HIV transmissions." AIDS. 2007;21(9):1218-20.
Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. "Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study." Clin. Infect. Dis.. 2012;55(5):631-8.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.

Pages